Although the aligned pathway is central to our work, the benefits of improved collaboration between MHRA and NICE go beyond it. A recent example is aficamten, a new daily pill for people with ...

Learn how NICE Advice’s system engagement service helps life sciences companies spot NHS adoption barriers before they become roadblocks.

Around 1,000 people with HER2-low advanced breast cancer can now be offered Enhertu after NICE recommended it for routine NHS use.

Hundreds of thousands of people with type 2 diabetes could swap daily insulin injections for a once-a-week jab, following a NICE recommendation today (Thursday, 20 August). The switch could cut the ...

Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (rapid review of TA992) [GID-TA12551] ...

There is a simple discount patient access scheme for lisocabtagene maraleucel. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Evidence-based recommendations on amivantamab (Rybrevant) with carboplatin and pemetrexed for untreated advanced non-small-cell lung cancer with activating EGFR exon 20 insertion mutations in adults.

There is a simple discount patient access scheme for vorasidenib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Evidence-based recommendations on ripretinib (Qinlock) for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors in adults. This guidance updates and replaces NICE ...

There is a commercial access agreement for pembrolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact keiron.hughes@msd.com ...

This quality standard covers diagnosing, managing and treating rare diseases in children, young people and adults. It describes high-quality care in priority areas for improvement. Rare diseases are ...

There is a simple discount patient access scheme for obe-cel. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact contact@autolus.com ...